Valuation: Agenus Inc.

Market Cap 255M 224M 207M 190M 360M 24.39B 367M 2.47B 968M 11.98B 957M 936M 41.37B P/E 2026 *
9.2x
P/E 2027 * -38.3x
Enterprise Value 255M 224M 207M 190M 360M 24.39B 367M 2.47B 968M 11.98B 957M 936M 41.37B EV / Sales 2026 *
1.38x
EV / Sales 2027 * 1.94x
Free-Float
93.28%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Agenus Inc.

1 day+82.69%
1 week+79.47%
Current month+100.00%
1 month+85.45%
3 months+47.47%
6 months+32.75%
Current year+94.90%
1 week 3.1
Extreme 3.1
8.7
1 month 2.85
Extreme 2.85
8.7
Current year 2.71
Extreme 2.71
8.7
1 year 2.71
Extreme 2.71
8.7
3 years 1.38
Extreme 1.38
36.8
5 years 1.38
Extreme 1.38
135.8
10 years 1.38
Extreme 1.38
149.8
Manager TitleAgeSince
Chief Executive Officer 72 31/03/1994
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/11/2021
Director TitleAgeSince
Chairman 72 04/11/2010
Director/Board Member 68 08/03/2007
Director/Board Member 68 07/12/2006
Date Insider Type Main position Quantity % Market Cap.
07-01Free

Director

8,547 0.0205%
07-01Free

Director

2,268 0.0054%
06-26Free

Chief Executive Officer

5,364 0.0129%
Change 5-day change 1-year change 3-year change Capi.($)
+82.69%+79.47%-13.31%-83.46% 255M
-1.22%+1.22%+2.98%+6.80% 50.61B
-1.57%-3.18%+383.82%+593.37% 39.11B
-0.14%+0.77%+27.49%-5.50% 34.64B
+1.76%-1.78%+21.44%+53.38% 33.79B
-0.06%-0.45%+2.94%+28.70% 26.89B
-1.93%-1.01% - - 16.47B
-1.49%-6.18%+63.89%+120.53% 15.14B
-1.35%-0.52%+13.96%+16.20% 13.85B
-0.97%-2.83%+10.35%-33.29% 12.72B
Average +7.57%+6.61%+57.06%+77.41% 24.35B
Weighted average by Cap. -0.56%-1.00%+80.20%+121.31%

Financials

2026 *2027 *
Net sales 185M 162M 150M 138M 261M 17.68B 266M 1.79B 701M 8.68B 694M 678M 29.98B 131M 115M 107M 98.25M 186M 12.58B 189M 1.27B 499M 6.18B 494M 483M 21.34B
Net income 44.8M 39.29M 36.39M 33.49M 63.34M 4.29B 64.57M 434M 170M 2.11B 168M 165M 7.27B -17.8M -15.61M -14.46M -13.3M -25.17M -1.7B -25.66M -172M -67.59M -837M -66.84M -65.38M -2.89B
Net Debt - -
Logo Agenus Inc.
Agenus Inc. is an immuno-oncology (I-O) company targeting cancer with a comprehensive pipeline of immunological agents. The company is focused on expanding patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants. Its I-O portfolio is driven by several platforms and programs, which include multiple antibody discovery platforms, antibody candidate programs, its saponin-based vaccine adjuvant platform, and a pipeline of novel allogeneic invariant natural killer T cell (iNKT) therapies for treating cancer and other immune-mediated diseases, controlled by MiNK. Its antibody candidate programs include botensilimab (BOT) and balstilimab (BAL) (a PD-1 blocking antibody). The Company has secured committed manufacturing capacity to support BOT+BAL supply needs for its clinical trials, global access programs and future commercialization.
Employees
81
Date Price Change Volume
13/07/26 $6.120 +82.69% 174,277,926
10/07/26 $3.350 +3.40% 833,400
09/07/26 $3.240 -0.31% 654,170
08/07/26 $3.250 -7.14% 797,540
07/07/26 $3.500 +2.64% 1,164,347
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
6.120USD
Average target price
30.00USD
Spread / Average Target
+390.20%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. AGEN Stock